# **Special Issue**

# Emerging Drug Candidates and Therapeutic Approaches for Ocular Disorders

# Message from the Guest Editor

This Special Issue, titled "Emerging Drug Candidates and Therapeutic Approaches for Ocular Disorders" extends a warm invitation to researchers and scholars from from various disciplines within the scientific community. We are seeking insightful research contributions that are dedicated to the exploration and validation of novel therapeutic targets and potential drug candidates for a wide spectrum of ocular disorders. The importance of this endeavor cannot be overstated, as eye diseases such as glaucoma, agerelated macular degeneration, diabetic retinopathy, dry eyes, cataracts, and various others continue to exert a substantial and often debilitating impact on a global scale.

Manuscripts submitted for this Special Issue should ideally provide mechanistic insights, demonstrating the efficacy or safety profiles of these newfound therapeutic targets and drug candidates. Our goal is to advance the field of ophthalmology by fostering a deeper understanding of ocular disorders and by paving the way for more effective and targeted treatment options.

## **Guest Editor**

Dr. Hongli Wu

Department of Pharmaceutical Sciences, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA

## Deadline for manuscript submissions

closed (13 September 2024)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/188677

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

